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S U M M A R Y
Objectives: The goal of this study was to provide a comprehensive analysis of the potential health impact
of universal vaccination of infants with the 7-valent pneumococcal conjugate vaccine (PCV7) in China.
Methods: A decision-analytic model designed for pneumococcal disease and outcomes of pneumococcal
infection was populated with local age-speciﬁc incidence and mortality data to estimate the expected
health beneﬁts of vaccinating birth cohorts of approximately 16 million infants per year over a 10-year
time horizon in China. The model incorporates both the direct impact on vaccinated children and the
indirect effect of herd protection on unvaccinated children and adults.
Results: The model predicts that more than 16.2 million cases of pneumococcal disease and 709 411
deaths could be prevented in China over the initial 10-year period following the introduction of the PCV7
vaccine. The majority of these health beneﬁts are due to the indirect effectiveness of the vaccine on the
unvaccinated population, resulting in approximately 10.8 million cases prevented and 636 371 lives
saved over 10 years.
Conclusions: The results suggest that a policy of universal PCV7 vaccination among infants in China
would have a substantial positive public health impact on the population of China.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Infectious diseases caused by Streptococcus pneumoniae are a
leading cause of respiratory infection globally. One of the most
important risk factors for pneumococcal disease is age, with young
children below the age of 5 years and elderly adults being at
highest risk. It is estimated that pneumococcal disease is the most
common cause of vaccine-preventable death in children under 5
years of age globally,1 and is a primary cause of mortality and
morbidity among children below the age of 5 years in China.2
The 7-valent pneumococcal conjugate vaccine (PCV7) contain-
ing the seven serotypes 4, 6B, 9 V, 14, 18C, 19F, and 23F, has been* Corresponding author. Tel.: +1 484 865 4487; fax: +1 646 441 6334.
E-mail address: Craig.roberts@pﬁzer.com (C.S. Roberts).
http://dx.doi.org/10.1016/j.ijid.2014.04.012
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).licensed for use in the USA since 2000. Out of the >91 known
pneumococcal serotypes, a relatively small number account for the
majority of pneumococcal disease globally.3,4 In China, it is
estimated that the seven serotypes contained in the PCV7 vaccine
would cover approximately 76% of the serotypes associated with
pneumococcal disease among children less than 5 years of age.5
Thus far, in countries where PCV7 has been incorporated into the
national immunization program, the full public health impact of
PCV7 on pneumococcal disease has been very positive, due largely
to the indirect effect of herd protection on unvaccinated children
and adults.6,7
There have been a number of studies demonstrating the
beneﬁcial impact of introducing PCV7 into the national immuni-
zation programs of various countries in Asia,8–13 however there has
not yet been a comprehensive analysis of the potential impact of
universal vaccination of infants with PCV7 in China. The objectiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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demographic and epidemiologic data to a mathematical model
designed to estimate the public health impact of PCV7 at the
population level.
2. Materials and methods
2.1. Model structure
A decision-analytic Markov state-transition model of pneumo-
coccal disease and vaccination was adapted to China by populating
the model with local Chinese speciﬁc incidence, mortality, and
serotype coverage data. The model, previously published as
applied to the US setting, estimates pneumococcal disease and
outcomes of pneumococcal infection in annual cycles over a 10-
year time horizon.14 At the time of writing, the only pneumococcal
vaccine available and approved for use in China was PCV7, so we
focused on the introduction of the PCV7 vaccine into the Chinese
population rather the 13-valent pneumococcal conjugate vaccine
(PCV13) that was applied to the US market.14
The clinical starting point of the model is the vaccination
strategy – comparing a case where no vaccinations are provided to
a policy of universal vaccination of all newborn infants in China
over a 10-year period. The population in the model is stratiﬁed into
10 age groups: <12 months, 12–23 months, 24–35 months, 36–47
months, 48–59 months, 5–17 years, 18–34 years, 35–49 years, 50–
64 years, and age 65+. Individuals within the model have a
probability of developing invasive pneumococcal disease (IPD;
bacteremia or meningitis), all-cause pneumonia, or all-cause otitis
media with varying probabilities of entering into each disease state
depending on the vaccination strategy and age of the individual.
The model also incorporates the possibility of developing long-
term complications resulting from meningitis (deafness or
disability). In order to capture the full beneﬁts of the PCV7
vaccine, health outcomes for the entire Chinese population were
incorporated into the model. These beneﬁts include both the direct
beneﬁts among the vaccinated and indirect beneﬁts due to herd
protection on the unvaccinated children and adults. Results areTable 1
Baseline disease incidence and case fatality rates
Parameter Age group (months)
<12 1
Annual incidence rates/100 000
IPD 11.56 
Hospitalized pneumonia 4654 
Percent of IPD that is meningitis 42% 
Percent of meningitis that results in deafness 13% 
Percent of meningitis that results in disability 7% 
Case-fatality rates
Meningitis 8.3% 
Bacteremia 11.5% 
Hospitalized pneumonia 4.8% 
Age group (years)
5–17 1
Annual incidence rates/100 000
IPD 63.39 
Hospitalized pneumonia 664 
Percent of IPD that is meningitis 23% 
Percent of meningitis that results in deafness 6% 
Percent of meningitis that results in disability 5% 
Case-fatality rates
Meningitis 8.8% 
Bacteremia 2.4% 
Hospitalized pneumonia 0.8% 
IPD, invasive pneumococcal disease.presented as raw estimates over ten years, as well as with future
outcomes discounted at 3% per year.
The rationale for applying a 10-year Markov model design, as
opposed to a transmission dynamic model, is that several reports of
the impact of the widespread use of PCV7 on disease have provided
robust data to estimate population-level effectiveness that ﬁt the
structure of a cohort-based model.6,15 Whereas transmission
dynamic models estimate the potential impact of the spread of
disease and can be useful to make predictions where the total
population effect may be highly uncertain, the 10-year Markov
framework allows direct application of vaccine impact based on
empirical evidence drawn from multiple ecological epidemiologic
studies. Many of the published models applied to evaluate the public
health and economic impact of PCVs in countries have similarly
applied cohort-based Markov estimations, presumably due to the
simplicity and transparency of the design, as well as the breadth of
existing data that are amenable to informing such models.13,14
2.2. Population and coverage rates
Estimates of the Chinese population by age for 2010 were based
on data from the Ministry of Health PRC 2009 Chinese Health
Statistical Annual Report.16 The sizes of incoming annual birth
cohorts used in the model were based on projections from the
international database of the US Census Bureau and were estimated
to be approximately 16 million births per year.17 At the initial point
of each model cycle, a new birth cohort enters the model and is
vaccinated. All adults and children born prior to the initial starting
point are considered unvaccinated during all stages in the model.
2.3. Disease incidence and case fatality rates
Baseline disease incidence rates and case fatality rates for
disease states included in the model are provided in Table 1. All-
cause mortality rates for deaths unrelated to pneumococcal
infection were included based on life tables for China in 2009.18
The incidence and case fatality rates for pneumococcal
meningitis among children under 5 years of age were derived from2–23 24–35 36–47 48–59
3.04 1.85 3.03 11.12
3823 3827 3830 3834
26% 18% 11% 3%
13% 13% 13% 13%
7% 7% 7% 7%
8.3% 8.3% 8.3% 8.3%
3.9% 0.0% 3.6% 2.6%
0.4% 0.4% 0.4% 0.4%
8–34 35–49 50–64 65+
10.71 11.30 12.62 42.86
113 215 443 3700
23% 25% 27% 16%
13% 13% 13% 13%
7% 7% 7% 7%
43.3% 51.1% 63.6% 76.8%
12.0% 13.9% 17.7% 28.8%
3.9% 5.1% 5.7% 10.0%
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meningitis was estimated to be 14 cases per 100 000 person-years,
of which 9.8% were estimated to be pneumococcal. To improve the
estimation of disease impact by age, an adjustment was applied
using data from a meta-analysis of international incidence rates and
estimates of the proportion of IPD cases by age group for children
under 5 years of age taken from the Center for Disease Control in
Taiwan.1,20 Incidence and case fatality rates for individuals 5 years
of age and older were derived using estimates of incidence from a
cost-effectiveness analysis of lower-middle income countries.13
Long-term sequelae resulting from meningitis infection were
assumed to occur to a proportion of meningitis survivors.21,22
The incidence of hospitalized pneumonia in children less than 5
years of age was derived using data from an analysis of child
mortality in China.2 To derive the incidence rates used in the model,
these mortality data were divided by case fatality rates of 4.8% for
infants under 1 year of age23 and 0.37% for children 1–4 years of age,
for a total case fatality rate of 1.4% for all children under 5 years of
age.19 Estimates of incidence and case fatality rates for ages 5–64
years were applied from those presented in an international cost-
effectiveness analysis.13 Data for persons 65 years of age and older
were taken from a previously published local analysis.23
2.4. Serotype distribution
Data from four studies identiﬁed in a systematic literature
review were used to estimate the serotype distribution for
pneumococcal meningitis and pneumonia in the model. The most
common serotypes were identiﬁed as 19F (52.7%), 23F (10.6%), 19A
(9.3%), 6B (6.7%), and 14 (5.9%). Based on this serotype distribution,
the coverage of PCV7 for China was estimated as 79.7% (95%
conﬁdence interval 47.9–94.3%).19
2.5. Vaccine effectiveness
2.5.1. Vaccine direct effectiveness
The direct effectiveness of the PCV7 vaccine on immunized
children in China in terms of percentage of reduction in disease
incidence relative to the pre-vaccine incidence rates for both IPD
and hospitalized pneumonia are presented in the top panel of
Table 2. In all cases, the estimated effectiveness in vaccinated
children during the year of birth was reduced by one third in order
to incorporate the fact that children less than 4 months of age may
not have received their initial dose and were, therefore, considered
to be unvaccinated during the initial period. The model also
assumes, consistent with the previous literature,21,24 that the
direct beneﬁts of vaccination begin to wane 2 years after the initialTable 2
Estimated direct and indirect effectiveness of PCV7 vaccination
Direct effectiveness (% reduction in disease)
Age group IPD Hospitalized pneumonia
<12 months 51.4% 16.2%
12–23 months 77.0% 24.3%
Indirect effectiveness (% reduction in disease)
Age group IPD Hospitalized pneumonia
<12 months 44.5% 28.2%
12–23 months 44.5% 28.2%
24–35 months 39.8% 8.4%
36–47 months 39.8% 8.4%
48–59 months 39.8% 8.4%
5–17 years 25.0% 12.9%
18–34 years 64.1% 16.9%
35–49 years 47.4% 15.1%
50–64 years 25.9% 13.8%
65+ years 47.5% 11.0%
IPD, invasive pneumococcal disease.dose to a level 91% of their initial effectiveness and that there is no
protection beyond the ﬁfth year after vaccination.
2.6. Direct effect on the reduction of IPD
The direct effectiveness of the PCV7 vaccine on the reduction of
IPD caused by covered serotypes was estimated from the immune
response in Chinese children as observed in a clinical trial and
applied to an accepted correlate of protection. On a population
basis, the effectiveness of PCV7 in preventing IPD from vaccine-type
serotypes correlates with a response 0.35 mg of antibody/ml, as
measured 4 weeks after the primary immunization series.25,26 This
correlate of protection has been recommended by a World Health
Organization Working Group as applicable on a global population
basis for assessing the likely efﬁcacy of future PCVs against IPD in
vaccinated infants and children less than 2 years of age.27
In order to estimate the local effectiveness of PCV7 on invasive
disease, efﬁcacy data were used from an immunogenicity study of
PCV7 that was conducted on healthy infants from Guangxi,
China.28 This randomized, controlled immunogenicity study
compared the level of antibody to pneumococcal antigens of
children who received PCV7 with DTaP (diphtheria–tetanus–
acellular pertussis) to a control group who received DTaP only. The
proportion of subjects who achieved >0.35 mg of pneumococcal
antibody/ml 30–50 days after the primary series by serotype were
4 (99%), 6B (83%), 9 V (98%), 14 (99%), 18C (99%), 19F (99%), and 23F
(94%).28 These data were multiplied by the respective serotype
prevalence locally to estimate an effectiveness of 96.9% reduction
in IPD versus covered serotypes in China.
2.6.1. Direct effect on hospitalized pneumonia
The direct effectiveness of PCV7 on hospitalized pneumonia was
derived from the observed effectiveness of PCV7 on the reduction of
X-ray-conﬁrmed pneumonia in US clinical trials.29 These data were
adjusted to account for Chinese serotype coverage derived from a
recent meta-analysis19 relative to US PCV7 serotype coverage at the
time of the studies, using the following conversion formula:
EPCV7_local = EPCV7_US  (CoveragePCV7_local/CoveragePCV7_US).
2.7. Vaccine indirect effectiveness
2.7.1. Indirect effectiveness on IPD
The estimated indirect effectiveness of PCV7 on IPD incidence
was derived from US invasive disease surveillance data by applying
the observed reductions in overall disease incidence from PCV7
serotypes to relative serotype coverage of PCV7 in China. Data from
US surveillance 7 years following the introduction of PCV7 were
used as the basis of estimation.15 For children under 5 years of age,
the estimated impact of direct effects were subtracted from the
overall disease reduction so that the indirect effect estimate only
comprised the additional reduction expected due to herd effects.
For children and adults over 5 years of age the net reduction in IPD
from the pre-PCV7 period to 7 years following the initial
introduction of PCV7 in the USA were applied.
2.7.2. Indirect effectiveness on hospitalized pneumonia
The estimated indirect effectiveness of PCV7 on hospitalized
pneumonia in children was derived by combining direct effective-
ness and ecologic data. Since it is unclear how much of the
observed decreases in hospitalized pneumonia are directly
attributable to PCV7, the midpoint of the direct effectiveness
from the PCV7 trial29–31 and reductions in disease from
observational studies were assumed to represent the total
effectiveness, both direct and indirect, of PCV7 on hospitalized
pneumonia.32–35 The overall indirect effectiveness for PCV7 in
China was obtained by multiplying the effectiveness of PCV7 by the
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PCV7 in China to the proportion of pneumonia cases caused by
serotypes covered by PCV7 in the USA at the time of its
introduction. Serotype coverage for pneumonia was assumed to
be the same as for IPD. Indirect effectiveness was derived from the
total effectiveness by assuming that all changes in incidence not
attributable to the direct impact of the vaccine were a result of
indirect effectiveness.
The indirect effectiveness of PCV7 against pneumonia in adults
was similarly derived from data regarding reductions in pneumonia
admissions following the introduction of PCV7 in the USA, again
adjusted to reﬂect serotype prevalence in China.36 In order to
account for the uncertainty regarding how much of the observed
reduction in pneumonia can be attributed to the introduction of the
PCV7 vaccine, it was assumed that the indirect effectiveness was
equal to 50% of the estimated effect reported by Grijalva et al.36
2.8. Utility weights
Utility values for various disease states were incorporated
into the model as a one-time reduction in the quality-adjustedTable 3
Estimated number of events over a 10-year time horizon
0% Discount No vaccine Vacci
Disease cases
<5 years of age
IPD 47 414 2
Hospitalized pneumonia 30 972 159 25 53
5+ years of age
IPD 3 102 072 3 10
Hospitalized pneumonia 72 142 665 72 14
All ages
IPD 3 149 486 3 12
Hospitalized pneumonia 103 114 824 97 68
Deaths due to disease
<5 years of age
IPD 2776 
Hospitalized pneumonia 433 120 36
5+ years of age
IPD 451 745 45
Hospitalized pneumonia 4 614 345 4 61
All ages
IPD 454 521 45
Hospitalized pneumonia 5 047 465 4 97
3% Discount No Vaccine Va
Disease cases
<5 years of age
IPD 41 627 20 57
Hospitalized pneumonia 27 189 357 22 52
5+ years of age
IPD 2 731 610 2 73
Hospitalized pneumonia 63 256 535 63 25
All ages
IPD 2 773 237 2 75
Hospitalized pneumonia 90 445 892 85 78
Deaths due to disease
<5 years of age
IPD 2440 
Hospitalized pneumonia 380 834 31
5+ years of age
IPD 395 899 39
Hospitalized pneumonia 4 034 959 4 03
All ages
IPD 398 339 39
Hospitalized pneumonia 4 415 793 4 35
IPD, invasive pneumococcal disease.life-years (QALY) for each disease occurrence in the year in the
annual cycle in which it occurs. The values of the reductions were
0.0232 for meningitis, 0.0079 for bacteremia, and 0.006 for
hospitalized pneumonia.37 Utility weights for deafness and disabili-
ty resulting from meningococcal complications were taken from
published sources and valued at 0.73 for deafness and 0.68 for
disability foreachyearovertheremainderoftheindividual’s life.38,39
3. Results
A summary of the key results is provided in Tables 3 and 4.
Given the available evidence suggesting the importance of the
indirect effect related to the PCV7 vaccine, we present the
combined direct and indirect results as the primary base case
and present the direct only effect purely as an additional sensitivity
analysis. The model estimates that, with no pneumococcal
vaccination, approximately 3.1 million cases of IPD and 103
million cases of hospitalized pneumonia would occur in China over
a 10-year period, leading to 5.5 million deaths. Of these totals,
approximately 31 million cases of disease and more than 435 000
deaths would occur in children under the age of 5 years.ne (Direct effect only) Vaccine (Direct and indirect effects)
2 862 16 481
8 787 22 379 637
2 148 2 266 070
3 464 65 310 056
5 010 2 282 551
2 251 87 689 693
1325 919
1 523 293 230
1 748 301 450
4 352 4 196 977
3 073 302 369
5 875 4 490 207
ccine (Direct effect only) Vaccine (Direct and indirect effects)
4 15 057
5 362 19 830 032
1 670 2 019 375
7 173 57 446 892
2 244 2 034 432
2 535 77 276 924
1179 831
8 271 260 007
5 902 268 181
4 964 3 680 772
7 081 269 012
3 235 3 940 779
Table 4
Clinical impact of routine infant vaccination: PCV7 vs. no vaccination
All ages <5 years of age 5+ years of age
0% Discounting Direct only Indirect only Total Direct only Indirect only Total Direct only Indirect only Total
Cases avoided
IPD 24 477 842 458 866 935 24 553 6381 30 934 (76) 836 077 836 001
Hospitalized pneumonia 5 432 573 9 992 558 15 425 131 5 433 372 3 159 150 8 592 522 (799) 6 833 409 6 832 610
Total 5 457 050 10 835 017 16 292 067 5 457 925 3 165 531 8 623 456 (875) 7 669 486 7 668 611
Deaths avoided
IPD 1448 150 704 152 152 1451 406 1857 (3) 150 298 150 295
Hospitalized pneumonia 71 592 485 667 557 259 71 598 68 293 139 891 (6) 417 374 417 368
Total 73 040 636 371 709 411 73 049 68 699 141 748 (9) 567 672 567 663
QALYs gained 4 845 621 15 032 321 19 877 941 4 848 624 4 549 357 9 397 980 (3003) 10 482 964 10 479 961
Life-years saved 5 438 442 17 674 717 23 113 159 5 441 833 5 128 223 10 570 057 (3391) 12 546 494 12 543 102
All ages <5 years of age 5+ years of age
3% Discounting Direct only Indirect only Total Direct only Indirect only Total Direct only Indirect only Total
Cases avoided
IPD 20 992 717 812 738 804 21 053 5517 26 570 (61) 712 295 712 234
Hospitalized pneumonia 4 663 357 8 505 612 13 168 969 4 663 995 2 695 330 7 359 325 (638) 5 810 281 5 809 643
Total 4 684 350 9 223 423 13 907 773 4 685 048 2 700 847 7 385 895 (699) 6 522 576 6 521 877
Deaths avoided
IPD 1258 128 068 129 326 1260 348 1608 (2) 127 720 127 718
Hospitalized pneumonia 62 558 412 456 475 014 62 563 58 264 120 827 (5) 354 192 354 187
Total 63 816 540 524 604 340 63 823 58 612 122 435 (7) 481 912 481 905
QALYs gained 2 027 283 8 458 042 10 485 324 2 028 598 1 890 720 3 919 318 (1315) 6 567 322 6 566 006
Life-years saved 2 169 329 9 845 522 12 014 851 2 170 757 2 039 881 4 210 638 (1428) 7 805 641 7 804 214
IPD, invasive pneumococcal disease; QALY, quality-adjusted life-year.
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of cases and deaths related to pneumococcal disease over the 10-
year period. The model predicts that routine PCV7 vaccination
among infants in China would result in a reduction of 866 935 cases
of IPD, 15.4 million cases of all-cause hospitalized pneumonia, and
709 411 deaths over the 10-year period. Among these, approxi-
mately 8.6 million cases of pneumococcal disease and 141 748
deaths would be avoided among children below the age of 5 years.
In older children and adults, the model predicts that approximately
7.6 million cases of disease could be prevented and 567 663 lives
could be saved, all attributable to the indirect effectiveness of the
vaccination. Overall, the direct effectiveness of the vaccination is
estimated to result in a reduction of disease cases by approximately
5.4 million and 73 040 lives saved, while the herd protection that is
expected to develop following the inclusion of the PCV7 vaccine
into the routine infant vaccination schedule is expected to reduce
the number of pneumococcal disease cases by 10.8 million over the
10-year period and save more than 630 000 lives.
The estimated direct health impact of vaccination is apparent
soon after the initial introduction of the vaccine, with signiﬁcant
reductions in IPD and pneumonia in children below the age of-250 0
-200 0
-150 0
-100 0
-500
0
Year 10Year 9Year 8Year 7Year 6Year 5Year 4Year 3Year 2Year 1Year 0
< 2 yrs, no  herd 2- 4 yrs,  no herd
< 2 yrs, herd 2- 4 yrs, herd
Figure 1. Estimated reduction in invasive pneumococcal disease cases with PCV7
over 10 years in children <5 years of age, with and without indirect (herd) effects.2 years observable within the ﬁrst 2 years following the inclusion
of PCV7 into the infant immunization schedule. These patterns are
shown in Figures 1 and 2. The overall estimated health beneﬁts
continue to grow through the ﬁrst 7 years after starting a
vaccination program as each incoming cohort continues to beneﬁt
from the direct protection as they progress through the model and,
more importantly, the indirect effectiveness of the vaccine
continues to expand into the older population.
4. Discussion
The model predicts that including PCV7 into the national
immunization program for infants in China would reduce the
incidence of IPD by 866 935, reduce all-cause hospitalized pneumo-
nia by approximately 15.4 million, and save approximately 709 411
lives over the initial 10-year period following the introduction of the
vaccine. A signiﬁcant portion of these beneﬁts is attributable to
indirect protection in the unvaccinated, which accounts for over 66%
of the cases prevented and 89.7% of the deaths averted. The net
impact of indirect effectiveness is a critical component of the value of
vaccination and there is substantial evidence to support the-600,000
-500,000
-400,000
-300,000
-200,000
-100,000
0
Year 10Year 9Year 8Year 7Year 6Year 5Year 4Year 3Year 2Year 1Year 0
< 2 yr s,  no  herd 2-4 yrs,  no herd
< 2 yrs, herd 2-4 yr s, herd
Figure 2. Estimated reduction in hospitalized pneumonia cases with PCV7 over 10
years in children <5 years of age, with and without indirect (herd) effects.
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populations following widespread use of PCV7.36,40
The study, as implemented, is subject to a number of limitations
regarding data availability. The analysis required extrapolation of
several parameters from local and international epidemiologic data
to derive necessary age-speciﬁc incidence rates, further complicated
by the limited availability of local disease estimates and the high
variability in the estimates that were available. The model used an
incidence of pneumococcal meningitis of 1.33 per 100 000, derived
from a thorough literature review and meta-analysis, which reported
an incidence rate of 14/100 000 for all-cause meningitis, 9.8% of
which was pneumococcal.19 Two international studies, however,
estimate pneumococcal meningitis rates of 10.5 to 14.3 per 100 000,
far above the rates we estimated from the local literature.1,13 It is
likely, therefore, that incidence rates used are an underestimate of
the true incidence rate of pneumococcal meningitis and the
estimated beneﬁts from PCV7 on pneumococcal meningitis derived
by this model will be conservative.
Reductions in hospitalized pneumonia are the greatest contrib-
utor of morbidity and mortality beneﬁts estimated by the model,
with an estimated 15.4 million cases and more than 500 000
deaths avoided. A recent analysis, however, suggests that
pneumonia deaths in China vary greatly across provinces and
over time, rendering estimates from historical, individual studies
unreliable.2 Additionally, estimates in the literature of the
incidence among children less than 5 years of age in China of
all-cause pneumonia are also highly variable, ranging from 4776 to
22 700 per 100 000 population19 to 6000 to 66 000 per 100 000.23
The estimates used in the model were derived from a more
contemporary analysis of mortality reports from across China for
2008,2 and estimated outputs are more conservative than reported
in previous published estimates.19,23
Further, for children over 5 years of age and adults, we sought to
derive incidence and mortality rates of all-cause hospitalized
pneumonia consistent with the broad pneumonia deﬁnition
applied to effectiveness studies similar to that from which our
herd effect assumption is based,33,34,36,40 but such measures were
not available. Among these values, the most inﬂuential in the
model was the assumption of pneumonia incidence in adults older
than 65 years of age. Our estimate of 3700 per 100 000 in adults
over 65 years of age was a direct estimate from a local study,23 but
is higher than incidence rates reported in Hong Kong (1600/
100 000),11 Taiwan (2165/100 000),10 Malaysia (2041/100 000),9
and Singapore (1939/100 000, age 60 years).12 More research on
the incidence, etiology, and mortality of hospitalized pneumonia in
adults is necessary to understand the potential impact of
pneumococcal vaccination on disease in China.
In conclusion, applying Chinese speciﬁc demographic and
epidemiologic data to a mathematical model designed to estimate
the public health impact, both direct and indirect, of PCV7 at the
population level, resulted in signiﬁcant estimated reductions in
morbidity and mortality from pneumococcal-related diseases for
all age groups in China. The model estimated that more than 16.2
million cases of pneumococcal-related disease and 709 411 deaths
could be prevented in China over the initial 10-year period
following the introduction of the PCV7 vaccine. The majority of the
health beneﬁts were due to the indirect effectiveness of the vaccine
on the unvaccinated population, resulting in approximately 10.8
million cases prevented and 636 371 lives saved, primarily among
adults and children over the age of 5 years. It is likely that a policy
of universal PCV7 vaccination among infants in China would be a
cost-effective health care intervention and have a substantial
positive public health impact on the population of China.
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